Zymeworks Just Bought a Lung Drug Company. The Reason Why Is Brilliant.
Zymeworks, a cancer-focused antibody company, is spending $929 million on a respiratory drug maker. The deal structure is so clever that Wall Street analysts are actually impressed. Here's why a lung inhaler might be the smartest thing to ever happen to an oncology pipeline.
A Cancer Biotech Walks Into a Respiratory Bar
Zymeworks is known for one thing: engineering clever cancer-fighting antibodies. Bispecific antibodies, antibody-drug conjugates, the kind of molecular origami that gets oncologists excited. So when the company announced it was spending $929 million to buy Theravance Biopharma, a company whose crown jewel is a lung disease inhaler, the biotech world did a collective double-take.
But look closer, and this deal is less "identity crisis" and more "financial chess move."
What Zymeworks Is Actually Buying
Theravance Biopharma isn't a splashy pipeline story. It's a cash flow machine wrapped in a modest market cap.
The headliner is YUPELRI (revefenacin), the first and only once-daily nebulized bronchodilator approved in the U.S. for COPD maintenance. Think of it as the slow, steady rent check: not glamorous, but reliable. Theravance collects a profit share on YUPELRI through its partnership with Viatris, and that stream of income is predictable enough that a lender was willing to finance a huge chunk of this deal against it (more on that in a second).
Then there's the royalty stream from TRELEGY ELLIPTA, one of the best-selling respiratory treatments on the planet. Theravance expects a $100 million milestone from that program in Q1 2027. That's not a maybe. It's the kind of near-term payout that makes deal math a lot friendlier.
Finally, there's ampreloxetine, an investigational drug in a Phase 3 trial for a rare condition called neurogenic orthostatic hypotension in patients with multiple system atrophy. Translation: it helps people whose blood pressure crashes dangerously when they stand up. This one is higher risk, higher reward, and Zymeworks structured the deal to reflect that uncertainty.
The Financing Is the Real Story
Forget the headline number for a moment. The way Zymeworks is paying for this deal is where it gets creative.
Zymeworks is offering for all of Theravance's stock. But it's not writing a $929 million check from its own bank account. Not even close.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
